Amgen Inc. $AMGN Position Lessened by OLD National Bancorp IN

Key Points

• OLD National Bancorp IN reduced its Amgen stake by 17.8%, selling 3,306 shares and finishing the quarter with 15,238 shares valued at about $4.99 million.
• Analyst sentiment is mixed: MarketBeat shows a consensus "Hold" rating with a $356.62 price target, amid divergent moves such as Bernstein's downgrade and a few upgrades from other firms.
• Amgen beat Q4 estimates with $5.29 EPS (vs. $4.76) and $9.87B revenue and set FY2026 guidance of 21.600–23.000 EPS (analysts expect ~22.18). The company also declared a quarterly dividend of $2.52 per share (2.9% yield).

OLD National Bancorp IN decreased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 17.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,238 shares of the medical research company's stock after selling 3,306 shares during the period. OLD National Bancorp IN's holdings in Amgen were worth $4,988,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company's stock worth $157,584,000 after purchasing an additional 43,884 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in Amgen by 2.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company's stock valued at $45,334,000 after acquiring an additional 3,619 shares in the last quarter. Curtis Advisory Group LLC bought a new stake in Amgen during the 4th quarter valued at $1,669,000. Davis Capital Management bought a new stake in Amgen during the 3rd quarter valued at $1,841,000. Finally, D.A. Davidson & CO. raised its stake in Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company's stock valued at $68,590,000 after acquiring an additional 6,222 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Wall Street Analyst Weigh In

AMGN has been the topic of several recent analyst reports. Sanford C. Bernstein downgraded Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 target price on the stock. in a research note on Tuesday, January 20th. Wall Street Zen raised Amgen from a "hold" rating to a "buy" rating in a research note on Saturday, April 11th. Deutsche Bank Aktiengesellschaft lifted their target price on Amgen from $285.00 to $295.00 and gave the company a "hold" rating in a research note on Thursday, February 5th. Leerink Partners reaffirmed a "market perform" rating and set a $355.00 target price on shares of Amgen in a research note on Thursday, March 5th. Finally, Freedom Capital downgraded Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $356.62.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Completed early-stage cancer study — Amgen announced completion of a Phase 1/2 MTAP‑null cancer combination study, a pipeline de‑risking milestone that could support long‑term value if follow‑up data are positive. Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study
• Positive Sentiment: Analyst price‑target lift — Guggenheim nudged its price target to $351 (from $347) ahead of earnings, a modest endorsement that may support the stock despite the firm keeping a Neutral rating. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings
• Neutral Sentiment: CTO retirement and leadership realignment — Amgen announced David M. Reese, M.D. will retire as EVP & Chief Technology Officer effective June 30, with a strategic leadership realignment emphasizing integration of biology and technology; operationally notable but framed as orderly. AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
• Neutral Sentiment: New/maintained Hold coverage — Bernstein and Canaccord Genuity are on Hold for AMGN (Canaccord initiated coverage with a Hold), indicating limited near‑term analyst conviction. Amgen (AMGN) Receives a Hold from Bernstein Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: Q1 earnings expected to decline — previews from Zacks/Yahoo suggest Amgen lacks the setup for an earnings beat in the upcoming Q1 report, creating downside risk around the release. Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline
• Negative Sentiment: Insider selling — filings show roughly US$4.1M of insider share sales over the past year, which some investors interpret as a cautionary signal. Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

Amgen Stock Up 0.8%

Shares of AMGN stock opened at $348.62 on Friday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The stock has a market cap of $188.14 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 3.62 and a beta of 0.47. The business's fifty day moving average is $361.24 and its 200-day moving average is $338.80. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to analysts' expectations of $9.46 billion. During the same period last year, the firm earned $5.31 EPS. The firm's revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts expect that Amgen Inc. will post 22.18 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen's dividend payout ratio (DPR) is 70.84%.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.